Design, synthesis, and in vitro biological evaluation of meta -sulfonamidobenzamide-based antibacterial LpxH inhibitors

Andrea Benediktsdottir,Sanjeewani Sooriyaarachchi,Sha Cao,Nina E. Ottosson,Stefan Lindström,Bo Lundgren,Katharina Klöditz,Daina Lola,Olga Bobileva,Einars Loza,Diarmaid Hughes,T. Alwyn Jones,Sherry L. Mowbray,Edouard Zamaratski,Anja Sandström,Anders Karlén
DOI: https://doi.org/10.1016/j.ejmech.2024.116790
IF: 7.088
2024-09-01
European Journal of Medicinal Chemistry
Abstract:New antibacterial compounds are urgently needed, especially for infections caused by the top-priority Gram-negative bacteria that are increasingly difficult to treat. Lipid A is a key component of the Gram-negative outer membrane and the LpxH enzyme plays an important role in its biosynthesis, making it a promising antibacterial target. Inspired by previously reported ortho-N -methyl-sulfonamidobenzamide-based LpxH inhibitors, novel benzamide substitutions were explored in this work to assess their in vitro activity. Our findings reveal that maintaining wild-type antibacterial activity necessitates removal of the N-methyl group when shifting the ortho-N-methyl-sulfonamide to the meta-position. This discovery led to the synthesis of meta-sulfonamidobenzamide analogs with potent antibacterial activity and enzyme inhibition. Moreover, we demonstrate that modifying the benzamide scaffold can alter blocking of the cardiac voltage-gated potassium ion channel hERG. Furthermore, two LpxH-bound X-ray structures show how the enzyme-ligand interactions of the meta -sulfonamidobenzamide analogs differ from those of the previously reported ortho analogs. Overall, our study has identified meta -sulfonamidobenzamide derivatives as promising LpxH inhibitors with the potential for optimization in future antibacterial hit-to-lead programs
chemistry, medicinal
What problem does this paper attempt to address?